[
  {
    "ts": null,
    "headline": "AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?",
    "summary": "Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.",
    "url": "https://finnhub.io/api/news?id=7a9f2523f52efcafe008ccb4dce422d8bdfa9797d514df51e044f9ad2751ea45",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760019240,
      "headline": "AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?",
      "id": 137033186,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.",
      "url": "https://finnhub.io/api/news?id=7a9f2523f52efcafe008ccb4dce422d8bdfa9797d514df51e044f9ad2751ea45"
    }
  },
  {
    "ts": null,
    "headline": "GSK's Hidden Growth Engines Beyond HIV And Oncology",
    "summary": "GSK plcâs strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating. Learn more about GSK stock here.",
    "url": "https://finnhub.io/api/news?id=ee4aebd4250ddb46bf7735456b5f1abe9d3ddd42dfabc80b324a2accb000cca8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760016130,
      "headline": "GSK's Hidden Growth Engines Beyond HIV And Oncology",
      "id": 137032881,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1193052383/image_1193052383.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "GSK plcâs strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating. Learn more about GSK stock here.",
      "url": "https://finnhub.io/api/news?id=ee4aebd4250ddb46bf7735456b5f1abe9d3ddd42dfabc80b324a2accb000cca8"
    }
  },
  {
    "ts": null,
    "headline": "SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer",
    "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the rollout of SkinMedica®'s reimagined packaging—a modernized look that elevates the consumer experience while advancing sustainability. The updated design features a refreshed logo, luxe copper accents, and intuitive navigation cues that make it easier for consumers to select the right products.",
    "url": "https://finnhub.io/api/news?id=27dbf56318369df775897960317fb1033218d55775a7668c35058bcd9595c09f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760011200,
      "headline": "SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer",
      "id": 137031223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the rollout of SkinMedica®'s reimagined packaging—a modernized look that elevates the consumer experience while advancing sustainability. The updated design features a refreshed logo, luxe copper accents, and intuitive navigation cues that make it easier for consumers to select the right products.",
      "url": "https://finnhub.io/api/news?id=27dbf56318369df775897960317fb1033218d55775a7668c35058bcd9595c09f"
    }
  },
  {
    "ts": null,
    "headline": "VIG: A Growth Fund Disguised As A Dividend ETF",
    "summary": "Discover how VIGâs growth-focused approach sets it apart from traditional dividend ETFs. Explore the impact of tech holdings and market cap weighting.",
    "url": "https://finnhub.io/api/news?id=5a7044edbb11b87fec1b74416adda1f36ed9fa38f7b67970ef027aced899c206",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760010918,
      "headline": "VIG: A Growth Fund Disguised As A Dividend ETF",
      "id": 137032518,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1340690117/image_1340690117.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover how VIGâs growth-focused approach sets it apart from traditional dividend ETFs. Explore the impact of tech holdings and market cap weighting.",
      "url": "https://finnhub.io/api/news?id=5a7044edbb11b87fec1b74416adda1f36ed9fa38f7b67970ef027aced899c206"
    }
  },
  {
    "ts": null,
    "headline": "REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting",
    "summary": "REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present interim data from the Phase II ALTITUDE® trial evaluating suprachoroidal delivery of surabgene lomparvovec (ABBV-RGX-314, sura-vec) for the treatment of diabetic retinopathy (DR) at the American Academy of Ophthalmology 2025 Annual Meeting. Sura-vec, developed in collaboration with AbbVie, is an investigational one-time gene therapy and potential first-in-class treatment for wet age-related macular degeneration (wet AMD) and DR.",
    "url": "https://finnhub.io/api/news?id=17d60086248b2a88eca1d3c14755495ad2d67c3a1772d0f5afa54aa01d339215",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760007900,
      "headline": "REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting",
      "id": 137031224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present interim data from the Phase II ALTITUDE® trial evaluating suprachoroidal delivery of surabgene lomparvovec (ABBV-RGX-314, sura-vec) for the treatment of diabetic retinopathy (DR) at the American Academy of Ophthalmology 2025 Annual Meeting. Sura-vec, developed in collaboration with AbbVie, is an investigational one-time gene therapy and potential first-in-class treatment for wet age-related macular degeneration (wet AMD) and DR.",
      "url": "https://finnhub.io/api/news?id=17d60086248b2a88eca1d3c14755495ad2d67c3a1772d0f5afa54aa01d339215"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New September Dividend Record - 100 Holdings With 13 Buys",
    "summary": "Discover September's top stock gains, AI-driven strategies, and high-yield BDC investments to boost passive income.",
    "url": "https://finnhub.io/api/news?id=8d23a2abebc98961046aa372ed04c412898c62c1483cedde798fbcf32b86519f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760004000,
      "headline": "My Dividend Stock Portfolio: New September Dividend Record - 100 Holdings With 13 Buys",
      "id": 137032129,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover September's top stock gains, AI-driven strategies, and high-yield BDC investments to boost passive income.",
      "url": "https://finnhub.io/api/news?id=8d23a2abebc98961046aa372ed04c412898c62c1483cedde798fbcf32b86519f"
    }
  },
  {
    "ts": null,
    "headline": "Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab",
    "summary": "The bispecific antibodies market presents key opportunities in oncology, autoimmune, and infectious diseases, driven by rapid technological advancements and strategic collaborations. Regional manufacturing and diverse supplier networks optimize supply chains, while innovation in antibody structures supports tailored therapies. Bispecific Antibodies Market Bispecific Antibodies Market Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The \"Bispecific Antibodies Market - Global Forecast 2025-2032\" report h",
    "url": "https://finnhub.io/api/news?id=d1948cb61301d64f144bdf4db2d55b6472eca18c5b1637ffc6ab4dc18bf7a5a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759998180,
      "headline": "Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab",
      "id": 137029703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The bispecific antibodies market presents key opportunities in oncology, autoimmune, and infectious diseases, driven by rapid technological advancements and strategic collaborations. Regional manufacturing and diverse supplier networks optimize supply chains, while innovation in antibody structures supports tailored therapies. Bispecific Antibodies Market Bispecific Antibodies Market Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The \"Bispecific Antibodies Market - Global Forecast 2025-2032\" report h",
      "url": "https://finnhub.io/api/news?id=d1948cb61301d64f144bdf4db2d55b6472eca18c5b1637ffc6ab4dc18bf7a5a4"
    }
  },
  {
    "ts": null,
    "headline": "How pharma giant AbbVie holds leaders accountable for culture",
    "summary": "The pharmaceutical company is one of the honorees on the Fortune 100 Best Companies to Work For Europe list in 2025.",
    "url": "https://finnhub.io/api/news?id=b4c2e477819fca0df305de2de6058db84a3127194ce87b2bd15445ca0702a560",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759989900,
      "headline": "How pharma giant AbbVie holds leaders accountable for culture",
      "id": 137030531,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The pharmaceutical company is one of the honorees on the Fortune 100 Best Companies to Work For Europe list in 2025.",
      "url": "https://finnhub.io/api/news?id=b4c2e477819fca0df305de2de6058db84a3127194ce87b2bd15445ca0702a560"
    }
  }
]